Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
- Six killed in cyclone off India's eastern coast
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- SanDisk stock falls ahead of earnings report
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025 8:01 AM ESTÂ Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch
 MESA open-label extension trial of sevasemten in Becker muscular dystrophy continues to enroll nearly all eligible participants
 Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025
Initiated Phase 1 healthy adult trial of EDG-15400 for future studies in Heart Failure
BOULDER, Colo., Nov. 6, 2025 /PRNewswire/... More



